94 related articles for article (PubMed ID: 21755563)
1. Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil.
Brentani A; de Castro G; Federico MH
Head Neck; 2011 Aug; 33(8):1199-205. PubMed ID: 21755563
[TBL] [Abstract][Full Text] [Related]
2. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.
Rose PG; Lappas PT
Gynecol Oncol; 2000 Jul; 78(1):3-6. PubMed ID: 10873400
[TBL] [Abstract][Full Text] [Related]
4. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
6. Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck.
Gourin CG; McAfee WJ; Neyman KM; Howington JW; Podolsky RH; Terris DJ
Laryngoscope; 2005 Aug; 115(8):1371-5. PubMed ID: 16094107
[TBL] [Abstract][Full Text] [Related]
7. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
9. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer.
Knegjens JL; Hauptmann M; Pameijer FA; Balm AJ; Hoebers FJ; de Bois JA; Kaanders JH; van Herpen CM; Verhoef CG; Wijers OB; Wiggenraad RG; Buter J; Rasch CR
Head Neck; 2011 Mar; 33(3):375-82. PubMed ID: 20629076
[TBL] [Abstract][Full Text] [Related]
10. Planned post-chemoradiation neck dissection: significance of radiation dose.
Stenson KM; Huo D; Blair E; Cohen EE; Argiris A; Haraf DJ; Vokes EE
Laryngoscope; 2006 Jan; 116(1):33-6. PubMed ID: 16481805
[TBL] [Abstract][Full Text] [Related]
11. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
Lang K; Sussman M; Friedman M; Su J; Kan HJ; Mauro D; Tafesse E; Menzin J
Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):582-8. PubMed ID: 19528407
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
13. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
15. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bone or cartilage invasion of locally advanced head and neck cancers.
Do L; Syed N; Puthawala A; Azawi S; Williams R; Vora N
Am J Clin Oncol; 2010 Dec; 33(6):591-4. PubMed ID: 20065851
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Tahara M; Minami H; Kawashima M; Kawada K; Mukai H; Sakuraba M; Matsuura K; Ogino T; Hayashi R; Ohtsu A
Cancer Sci; 2011 Feb; 102(2):419-24. PubMed ID: 21134076
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation.
Robbins KT; Doweck I; Samant S; Vieira F
Arch Otolaryngol Head Neck Surg; 2005 Nov; 131(11):965-9. PubMed ID: 16301367
[TBL] [Abstract][Full Text] [Related]
19. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck.
Lau H; Phan T; Mackinnon J; Matthews TW
Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):257-61. PubMed ID: 18347249
[TBL] [Abstract][Full Text] [Related]
20. Value of postoperative radiotherapy in patients with pathologic N1 neck disease.
Jäckel MC; Ambrosch P; Christiansen H; Martin A; Steiner W
Head Neck; 2008 Jul; 30(7):875-82. PubMed ID: 18302275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
